Compare commits

..

2 commits

Author SHA1 Message Date
Teleo Agents
8d778b5256 vida: research session 2026-04-30 — 9 sources archived
Pentagon-Agent: Vida <HEADLESS>
2026-04-30 04:54:57 +00:00
Teleo Agents
1c44a4a2b5 reweave: merge 18 files via frontmatter union [auto] 2026-04-30 04:48:24 +00:00

View file

@ -10,10 +10,18 @@ agent: vida
sourced_from: health/2026-04-28-omada-health-ipo-glp1-track-atoms-to-bits-validation.md
scope: causal
sourcer: Omada Health investor relations
supports: ["healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create"]
related: ["healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "weightwatchers-med-plus", "cgm-integrated-glp1-behavioral-support-achieves-superior-unit-economics-versus-coaching-only-models", "glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt"]
challenges: ["AI-driven GLP-1 telehealth prescribing achieves billion-dollar scale with minimal staffing but generates systematic safety and fraud failures"]
reweave_edges: ["AI-driven GLP-1 telehealth prescribing achieves billion-dollar scale with minimal staffing but generates systematic safety and fraud failures|challenges|2026-04-29"]
supports:
- healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create
related:
- healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create
- digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring
- weightwatchers-med-plus
- cgm-integrated-glp1-behavioral-support-achieves-superior-unit-economics-versus-coaching-only-models
- glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt
challenges:
- AI-driven GLP-1 telehealth prescribing achieves billion-dollar scale with minimal staffing but generates systematic safety and fraud failures
reweave_edges:
- AI-driven GLP-1 telehealth prescribing achieves billion-dollar scale with minimal staffing but generates systematic safety and fraud failures|challenges|2026-04-29
---
# CGM-integrated GLP-1 behavioral support achieves fundamentally different unit economics than coaching-only models, enabling profitability at lower revenue scales
@ -24,4 +32,4 @@ Omada Health achieved profitability ($5.16M net income) at $260M annual revenue
**Source:** WW Clinic 2026 program structure, Hit Consultant December 2025
WeightWatchers' diabetes program with FreeStyle Libre CGM shows strong clinical outcomes (0.9 HbA1c reduction at 6 months, 33.8% depression reduction, 62% physical function increase), but WW chose NOT to extend CGM to its general GLP-1 Med+ program despite having the Abbott partnership. This selective deployment—diabetes yes, obesity no—suggests either (a) CGM reimbursement constraints limit economic viability outside diabetes indication, or (b) organizational recognition that the physical integration moat works for diabetes but faces different economics in obesity market.
WeightWatchers' diabetes program with FreeStyle Libre CGM shows strong clinical outcomes (0.9 HbA1c reduction at 6 months, 33.8% depression reduction, 62% physical function increase), but WW chose NOT to extend CGM to its general GLP-1 Med+ program despite having the Abbott partnership. This selective deployment—diabetes yes, obesity no—suggests either (a) CGM reimbursement constraints limit economic viability outside diabetes indication, or (b) organizational recognition that the physical integration moat works for diabetes but faces different economics in obesity market.